Cargando…
PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy
Both preclinical and clinical data suggest that activation of the PI3K/AKT/mTOR pathway in response to hormonal therapy results in acquired endocrine therapy resistance. We evaluated differences in activation of the PI3K/AKT/mTOR pathway in estrogen receptor α (ERα) positive primary and correspondin...
Autores principales: | Beelen, Karin, Hoefnagel, Laurien DC, Opdam, Mark, Wesseling, Jelle, Sanders, J, Vincent, Andrew D, van Diest, Paul J, Linn, Sabine C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277331/ https://www.ncbi.nlm.nih.gov/pubmed/24501006 http://dx.doi.org/10.1002/ijc.28769 |
Ejemplares similares
-
Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot
por: Beelen, Karin, et al.
Publicado: (2018) -
Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases
por: Jiwa, Laura S, et al.
Publicado: (2014) -
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
por: Beelen, Karin, et al.
Publicado: (2014) -
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
por: Skolariki, Aglaia, et al.
Publicado: (2022) -
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
por: Beelen, Karin, et al.
Publicado: (2014)